Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.

@article{Loyet2014ComplementII,
  title={Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.},
  author={Kelly M Loyet and Jeremy Good and Teresa Davancaze and Lizette Sturgeon and Xiangdan Wang and Jihong Yang and Kha N Le and Maureen Wong and Philip E. Hass and Menno van Lookeren Campagne and Peter C Haughney and Alyssa M Morimoto and Lisa A. Damico-Beyer and Laura E Deforge},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2014},
  volume={351 3},
  pages={527-37}
}
Anti-factor D (AFD; FCFD4514S, lampalizumab) is a humanized IgG Fab fragment directed against factor D (fD), a rate-limiting serine protease in the alternative complement pathway (AP). Evaluation of AFD as a potential intravitreal (IVT) therapeutic for dry age-related macular degeneration patients with geographic atrophy (GA) is ongoing. However, it is unclear whether IVT administration of AFD can affect systemic AP activation and potentially compromise host-immune responses. We characterized… CONTINUE READING